AngioDynamics, Inc. (ANGO)
ANGO moved a median of +0.33% 30 minutes after news, and -0.14% by the close. How ANGO actually reacts to news — the realized, point-in-time move the market made, measured across 218 labeled events over the last three years with zero look-ahead.
ANGO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.33% | 66% | 218 |
| 30-min | +0.33% | 54% | 218 |
| 60-min | +0.11% | 55% | 218 |
| to close | -0.14% | 46% | 218 |
| Middle 50% of ANGO reactions | -1.43% to +1.25% |
|---|---|
| Median reaction (30-min) | +0.33% |
| Measured reactions | 218 |
Half of all AngioDynamics, Inc. news events land between -1.43% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ANGO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANGO's baseline. Nothing else.
Recent ANGO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer | Press release | Business Wire | +1.21% | +2.41% | |
| AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer | Press release | Business Wire | -3.15% | -12.74% | |
| AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability | Press release | Business Wire | -3.15% | -12.74% | |
| Form 10-Q ANGIODYNAMICS INC For: Aug 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.84% | |
| Form 8-K ANGIODYNAMICS INC For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | -3.15% | -12.74% | |
| Form 8-K ANGIODYNAMICS INC For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -3.15% | -12.74% | |
| Form DEF 14A ANGIODYNAMICS INC For: Nov 17 | SEC filing · Form DEF | SEC EDGAR | -3.15% | -12.74% | |
| Form DEFA14A ANGIODYNAMICS INC | SEC filing · Form DEFA14A | SEC EDGAR | +1.24% | -0.27% | |
| AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence | Press release | Business Wire | -1.96% | -1.37% | |
| Form 10-K/A ANGIODYNAMICS INC For: May 31 | SEC filing · Form 10-K | SEC EDGAR | -0.32% | +0.39% | |
| AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 | Press release | Business Wire | -0.32% | +0.39% | |
| AngioDynamics to Participate in Upcoming Investor Conferences | Press release | Business Wire | +1.66% | +3.39% | |
| AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability | Press release | Business Wire | -7.04% | -4.69% | |
| Form 10-K ANGIODYNAMICS INC For: May 31 | SEC filing · Form 10-K | SEC EDGAR | -0.91% | -1.06% | |
| Form 8-K ANGIODYNAMICS INC For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -7.04% | -4.69% | |
| AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026 | Press release | Business Wire | +0.53% | -1.44% | |
| AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH) | Press release | Business Wire | -0.74% | -3.61% | |
| AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect | Press release | Business Wire | +0.33% | -2.48% | |
| AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | +0.17% | -0.34% | |
| AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer | Press release | Business Wire | +0.58% | +0.37% | |
| Form 8-K ANGIODYNAMICS INC For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | -0.63% | |
| AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability | Press release | Business Wire | -0.62% | -8.84% | |
| Form 10-Q ANGIODYNAMICS INC For: Feb 28 | SEC filing · Form 10-Q | SEC EDGAR | +0.14% | -1.62% | |
| Form 8-K ANGIODYNAMICS INC For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -0.62% | -8.84% | |
| AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | Business Wire | +0.36% | +3.84% | |
| AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026 | Press release | Business Wire | -0.05% | +0.66% | |
| AngioDynamics to Present at the Leerink Partners Global Healthcare Conference | Press release | Business Wire | -0.71% | +1.51% | |
| AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform | Press release | Business Wire | -0.36% | +1.63% | |
| AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care | Press release | Business Wire | +1.81% | -4.28% | |
| AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance | Press release | Business Wire | +1.35% | +2.50% | |
| Form 8-K ANGIODYNAMICS INC For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +1.42% | -0.94% | |
| Form 8-K ANGIODYNAMICS INC For: Jan 14 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | +1.59% | |
| AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability | Press release | Business Wire | -3.10% | -8.99% | |
| Form 10-Q ANGIODYNAMICS INC For: Nov 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.10% | -0.27% | |
| Form 8-K ANGIODYNAMICS INC For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -3.10% | -8.99% | |
| AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026 | Press release | Business Wire | -0.11% | -2.81% | |
| AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +1.79% | +2.02% | |
| Form 8-K ANGIODYNAMICS INC For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | +0.40% | |
| AngioDynamics to Participate in the UBS Global Healthcare Conference | Press release | Business Wire | -0.41% | -0.41% | |
| Form S-8 ANGIODYNAMICS INC | SEC filing · Form S-8 | SEC EDGAR | +0.29% | +1.76% | |
| AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List | Press release | Business Wire | +3.53% | +0.81% | |
| AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum | Press release | Business Wire | -7.93% | -7.78% | |
| Form 10-Q ANGIODYNAMICS INC For: Aug 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.91% | -1.10% | |
| Form 8-K ANGIODYNAMICS INC For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | -7.93% | -7.78% | |
| Form DEF 14A ANGIODYNAMICS INC For: May 31 | SEC filing · Form DEF | SEC EDGAR | -1.22% | -1.03% | |
| Form DEFA14A ANGIODYNAMICS INC | SEC filing · Form DEFA14A | SEC EDGAR | -1.22% | -1.03% | |
| AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025 | Press release | Business Wire | -0.23% | +0.18% | |
| AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference | Press release | Business Wire | +1.76% | +0.00% | |
| AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia | Press release | Business Wire | +0.22% | -0.87% | |
| AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology | Press release | Business Wire | +0.63% | +0.66% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANGO section they belong to.
Where else ANGO is measured.
ANGO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Lipocine Inc. (LPCN) | 219 | +0.34% | 52% |
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
| Anixa Biosciences, Inc. (ANIX) | 217 | 0.00% | 49% |
| Entera Bio Ltd. - Ordinary Shares (ENTX) | 217 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AngioDynamics, Inc.'s median reaction calculated?
Every labeled ANGO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 218 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of ANGO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ANGO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.